

PALL CORP  
Form 10-Q  
March 18, 2003  
[Click here for Index](#)

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended February 1, 2003**

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number 1- 4311**

**PALL CORPORATION**

(Exact name of registrant as specified in its charter)

**New York**

(State or other jurisdiction of incorporation or  
organization)

**11-1541330**

(I.R.S. Employer Identification No.)

**2200 Northern Boulevard, East Hills, NY**

(Address of principal executive offices)

**11548**

(Zip Code)

**(516) 484-5400**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days. Yes  No

**The number of shares of the registrant's common stock outstanding as of March 5, 2003 was 123,008,220.**

---

---

---

**PALL CORPORATION**  
**FORM 10-Q for the Quarter Ended February 1, 2003**

**INDEX**

**Page No.**

---

**PART I. FINANCIAL INFORMATION**

|         |   |           |
|---------|---|-----------|
| Item 1. | Financial Statements (Unaudited)  |           |
|         | <u>Condensed Consolidated Balance Sheets at February 1, 2003 and August 3, 2002</u>   | <u>3</u>  |
|         | <u>Condensed Consolidated Statements of Earnings for the three and six months ended February 1, 2003 and January 26, 2002</u> | <u>4</u>  |
|         | <u>Condensed Consolidated Statements of Cash Flows for the six months ended February 1, 2003 and January 26, 2002</u>         | <u>5</u>  |
|         | <u>Notes To Condensed Consolidated Financial Statements</u>   | <u>6</u>  |
| Item 2. | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                                  | <u>14</u> |
| Item 4. | <u>Controls and Procedures</u>  | <u>21</u> |

**PART II. OTHER INFORMATION**

|         |  |                  |
|---------|--|------------------|
| Item 1. | <u>Legal Proceedings</u>                                   | <u>21</u>        |
| Item 4. | <u>Submission of Matters to a Vote of Security Holders</u> | <u>22</u>        |
| Item 6. | <u>Exhibits and Reports on Form 8-K</u>                    | <u>22</u>        |
|         | <b><u>SIGNATURES</u></b>                                   | <b><u>23</u></b> |

[Back to Index](#)**PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS.**

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands, except per share data)  
(Unaudited)

|  | Feb. 1, 2003 | Aug. 3, 2002 |
|--|--------------|--------------|
| <b>ASSETS</b>                                    |              |              |
| Current assets:                                  |              |              |
| Cash and cash equivalents                        | \$ 102,185   | \$ 105,224   |
| Short-term investments                           | 21,000       | 40,200       |
| Accounts receivable, net                         | 373,015      | 415,853      |
| Inventories                                      | 280,547      | 256,910      |
| Other current assets                             | 95,898       | 94,947       |
|  | 872,645      | 913,134      |
| Total current assets                             |              |              |
| Property, plant and equipment, net               | 607,727      | 605,095      |
| Goodwill, net                                    | 223,969      | 262,973      |
| Intangible assets, net                           | 53,394       | 39,948       |
| Other assets                                     | 205,186      | 189,293      |
|  | 1,962,921    | 2,010,443    |
| Total assets                                     | \$ 1,962,921 | \$ 2,010,443 |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>      |              |              |
| Current liabilities:                             |              |              |
| Accounts payable and other current liabilities   | \$ 254,039   | \$ 290,228   |
| Income taxes payable                             | 42,699       | 41,549       |
| Current portion of long-term debt                | 40,747       | 61,344       |
| Notes payable to banks                           | 20,521       | 42,202       |
|  | 358,006      | 435,323      |
| Total current liabilities                        |              |              |
| Long-term debt, net of current portion           | 598,838      | 619,705      |
| Deferred taxes and other non-current liabilities | 162,372      | 135,695      |
|  | 1,119,216    | 1,190,723    |
| Total liabilities                                | 1,119,216    | 1,190,723    |
| Stockholders' equity:                            |              |              |
| Common stock, par value \$.10 per share          | 12,796       | 12,796       |
| Capital in excess of par value                   | 110,078      | 110,745      |
| Retained earnings                                | 817,167      | 832,308      |
| Treasury stock, at cost                          | (106,030)    | (110,799)    |
| Stock option loans                               | (2,271)      | (3,259)      |
| Accumulated other comprehensive income (loss):   |              |              |
| Foreign currency translation                     | 17,951       | (17,429)     |
| Minimum pension liability                        | (3,103)      | (3,079)      |
| Unrealized investment losses                     | (1,980)      | (236)        |
| Unrealized losses on derivatives                 | (903)        | (1,327)      |
|  | 11,965       | (22,071)     |
| Total stockholders' equity                       | 843,705      | 819,720      |

Edgar Filing: PALL CORP - Form 10-Q

|  |    |           |    |           |
|--|----|-----------|----|-----------|
| Total liabilities and stockholders' equity | \$ | 1,962,921 | \$ | 2,010,443 |
|--|----|-----------|----|-----------|

See accompanying notes to condensed consolidated financial statements.

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS**  
(In thousands, except per share data)  
(Unaudited)

|  | Three Months Ended |               | Six Months Ended |               |
|--|--------------------|---------------|------------------|---------------|
|  | Feb. 1, 2003       | Jan. 26, 2002 | Feb. 1, 2003     | Jan. 26, 2002 |
| Net sales                                    | \$ 388,522         | \$ 285,435    | \$ 720,732       | \$ 559,554    |
| Cost of sales                                | 200,085            | 145,394       | 374,346          | 280,464       |
| Gross profit                                 | 188,437            | 140,041       | 346,386          | 279,090       |
| Selling, general and administrative expenses | 128,837            | 101,152       | 245,697          | 199,226       |
| Research and development                     | 12,415             | 12,468        | 25,460           | 25,315        |
| Restructuring and other charges              | 924                |               | 41,299           |               |
| Interest expense, net                        | 6,207              | 2,815         | 13,473           | 6,078         |
| Earnings before income taxes                 | 40,054             | 23,606        | 20,457           | 48,471        |
| Income taxes                                 | 8,675              | 5,191         | 12,216           | 10,664        |
| Net earnings                                 | \$ 31,379          | \$ 18,415     | \$ 8,241         | \$ 37,807     |
| Earnings per share:                          |                    |               |                  |               |
| Basic  | \$ 0.26            | \$ 0.15       | \$ 0.07          | \$ 0.31       |
| Diluted                                      | \$ 0.25            | \$ 0.15       | \$ 0.07          | \$ 0.31       |
| Dividends declared per share                 | \$ 0.09            | \$ 0.17       | \$ 0.18          | \$ 0.34       |
| Average shares outstanding:                  |                    |               |                  |               |
| Basic  | 122,948            | 122,151       | 122,893          | 122,200       |
| Diluted                                      | 123,551            | 123,408       | 123,612          | 123,530       |

See accompanying notes to condensed consolidated financial statements.

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands)  
(Unaudited)

|  | Six Months Ended |               |
|--|------------------|---------------|
|  | Feb. 1, 2003     | Jan. 26, 2002 |
| Net cash provided by operating activities, net of effect of acquisitions | \$ 75,097        | \$ 63,602     |
| <b>Investing activities:</b>   |                  |               |
| Acquisition of business  | (8,125)          |               |
| Capital expenditures   | (28,235)         | (33,919)      |
| Disposals of fixed assets  | 2,707            | 1,164         |
| Short-term investments   | 19,200           | 77,900        |
| Benefits protection trust  |                  | (1,562)       |
|  | (14,453)         | 43,583        |
| <b>Financing activities:</b>   |                  |               |
| Notes payable  | (373,339)        | (17,931)      |
| Long-term borrowings   | 445,004          | 1,034         |
| Repayments of long-term debt   | (130,921)        | (44,530)      |
| Net proceeds from stock plans  | 3,868            | 10,993        |
| Proceeds from termination of interest rate swaps                         | 7,533            |               |
| Purchase of treasury stock   |                  | (9,999)       |
| Dividends paid   | (22,105)         | (41,542)      |
|  | (69,960)         | (101,975)     |
| Cash flow for period   | (9,316)          | 5,210         |
| Cash and cash equivalents at beginning of year                           | 105,224          | 54,927        |
| Effect of exchange rate changes on cash                                  | 6,277            | (1,079)       |
|  | 102,185          | 59,058        |
| Cash and cash equivalents at end of period                               | \$ 102,185       | \$ 59,058     |
| <b>Supplemental disclosures:</b>   |                  |               |
| Interest paid  | \$ 6,742         | \$ 10,245     |
| Income taxes paid (net of refunds)                                       | 10,038           | 19,483        |

See accompanying notes to condensed consolidated financial statements.

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(In thousands, except per share data)**  
**(Unaudited)**

**NOTE 1 BASIS OF PRESENTATION**

The financial information included herein is unaudited. However, such information reflects all adjustments which are, in the opinion of management, necessary to present fairly the Company's financial position, results of operations and cash flows as of the dates and for the periods presented herein. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company's Annual Report on Form 10-K for the fiscal year ended August 3, 2002.

Certain prior year amounts have been reclassified to conform with current year presentation.

**NOTE 2 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

In January 2003, the Company adopted the provisions of the Financial Accounting Standards Board's (FASB) Statement of Financial Accounting Standard (SFAS) No. 146, Accounting for Costs Associated with Exit or Disposal Activities (SFAS No. 146). SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. The adoption of this accounting pronouncement did not have a material effect on the Company's results of operations, cash flows or financial position.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation Transition and Disclosure (SFAS No. 148), which amends SFAS No. 123, Accounting for Stock-Based Compensation (SFAS No. 123). SFAS No. 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. SFAS No. 148 also amends the disclosure provisions of SFAS No. 123 to require prominent disclosure about the effects on reported net income of an entity's accounting policy decisions with respect to stock-based employee compensation, and requires disclosure about those effects in both annual and interim financial statements. SFAS No. 148 is effective for the Company's third quarter of fiscal 2003. The Company has elected to continue to apply Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees in accounting for its stock compensation plans. Therefore, the adoption of SFAS No. 148 is not expected to have an impact on the Company's consolidated results of operations, cash flows or financial position.

In December 2002, the Company adopted the provisions of FASB Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others (FIN No. 45). The adoption of FIN No. 45 did not have a material effect on the Company's results of operations, cash flows or financial position.

In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities (FIN No. 46). FIN No. 46 requires that if an entity has a controlling financial interest in a variable interest entity, the assets, liabilities and results of activities of the variable interest entity should be included in the consolidated financial statements of the entity. FIN No. 46 requires that its provisions are effective immediately for all arrangements entered into after January 31, 2003. As the Company does not have any variable interest entities, the adoption of FIN No. 46 is not expected to have an impact on the Company's consolidated results of operations, cash flows or financial position.

**NOTE 3 ACQUISITION**

On April 24, 2002, the Company acquired the Filtration and Separations Group (FSG) from United States Filter Corporation (US Filter) for \$360,000 in cash, subject to a post closing adjustment of the purchase price based on the net assets acquired as of April 27, 2002. The adjustment to the purchase price was finalized in the first quarter of fiscal 2003, resulting in additional consideration due to US Filter of \$7,801. The operating results of FSG are reported in the Company's results of operations from April 28, 2002.

The acquisition was accounted for using the purchase method of accounting in accordance with SFAS No. 141, Business Combinations (SFAS No. 141). SFAS No. 141 requires that the total cost of the acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. In the first quarter of fiscal 2003, the valuation of in-process research and development and certain amortizable

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

intangible assets, patented and unpatented technology, was finalized. As a result, the Company wrote-off \$37,600 of preliminary goodwill as in-process research and development (refer to Note 4 for further discussion) and reallocated \$16,800 of preliminary goodwill to write up the aforementioned amortizable intangible assets from their book value to their fair value of \$20,100.

The amount of in-process research and development was determined by identifying research projects for which technological feasibility had not been established and for which no alternative future uses existed. As of the acquisition date, there were various projects that met the above criteria. The majority of the projects identified are targeted for the General Industrial segment. The value of the research projects identified to be in process was determined by estimating the future cash flows from the projects once commercially feasible, discounting the net cash flows back to their present value and then applying a percentage of completion to the calculated value. The key assumptions specifically underlying the valuation for purchased in-process research and development consist of an expected completion date for the in-process projects, estimated costs to complete the projects, revenue and expense projections, and discount rates based on the risks associated with the development life cycle of the in-process technology acquired. The weighted average discount rate used was approximately 24% (ranging from 18% to 67%). The percentage of completion for the projects was determined using milestones representing estimates of effort, value added and degree of difficulty of the portion of the projects completed as of April 27, 2002, as compared to the total research and development to be completed to bring the projects to technological feasibility. As of April 27, 2002, the Company estimates the projects were approximately 67% complete on a weighted average basis (ranging from 2% to 96%). The development of these technologies remains an uncertainty due to the remaining efforts to achieve technological feasibility, changing customer markets, and significant competitive threats from other companies.

At the date of acquisition, management began formulating integration plans which contemplate the closure of redundant facilities and the sale of certain businesses. In addition, the synergies created by joining the two organizations have resulted in employee terminations. The condensed consolidated balance sheets at February 1, 2003 and August 3, 2002 reflect liabilities for such items; however, we will continue to finalize and announce other integration plans during fiscal 2003. Finalization of integration plans concerning FSG's facilities and employees in the third quarter will be reported as increases and decreases to goodwill and to the assets acquired and liabilities assumed whereas the financial statement impact of any other integration plans will be reflected in earnings during fiscal year 2003 (refer to Note 4 for discussion of actions taken in the first six months of fiscal 2003).

The February 1, 2003 condensed consolidated balance sheet reflects the preliminary allocation of the purchase price and goodwill, which is not tax deductible, of \$166,709. The following table summarizes the preliminary allocation of the purchase price to the assets and in-process research and development acquired and liabilities assumed:

|   |            |
|---|------------|
| Purchase price  | \$ 367,801 |
| Transaction costs   | 7,159      |
|   | <hr/>      |
| Total cost  | 374,960    |
| Cash acquired   | 19,671     |
|   | <hr/>      |
| Total purchase price, net of cash acquired                    | 355,289    |
|   | <hr/>      |
| Current assets  | 168,673    |
| Property, plant and equipment                                 | 92,149     |
| Intangible assets   | 23,617     |
| Other non-current assets                                      | 3,900      |
| In-process research and development                           | 37,600     |
|   | <hr/>      |
| Total assets and in-process research and development acquired | 325,939    |
|   | <hr/>      |
| Current liabilities   | 102,073    |
| Non-current liabilities                                       | 35,286     |
|   | <hr/>      |
| Total liabilities assumed                                     | 137,359    |
|   | <hr/>      |



Edgar Filing: PALL CORP - Form 10-Q

Goodwill

\$ 166,709

7

---

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

Goodwill has been allocated preliminarily to the Company's reportable segments as follows:

|                    |            |
|--------------------|------------|
| BioPharmaceuticals | \$ 12,653  |
| General Industrial | 133,401    |
| Microelectronics   | 20,655     |
|                    | <hr/>      |
| Total              | \$ 166,709 |
|                    | <hr/>      |

**NOTE 4 RESTRUCTURING AND OTHER CHARGES**

The following table summarizes the restructuring related items and other charges recorded for the quarter and six months ending February 1, 2003:

| Three Months Ended Feb. 1, 2003                | Restructuring | Other<br>Charges and<br>Adjustments | Total<br>Charged To<br>Earnings | Adjustments to<br>Goodwill (a) | Total    |
|--|---------------|-------------------------------------|---------------------------------|--------------------------------|----------|
| Severance (c)                                  | \$ 652        | \$                                  | \$ 652                          | \$ 1,325                       | \$ 1,977 |
| Asset write-offs (c)                           | 205           |                                     | 205                             | 2,040                          | 2,245    |
| Lease termination liabilities and<br>other (c) | 67            |                                     | 67                              | 626                            | 693      |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>    |
| Total  | \$ 924        | \$                                  | \$ 924                          | \$ 3,991                       | \$ 4,915 |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>    |
| Cash   | \$ 719        | \$                                  | \$ 719                          | \$ 1,951                       | \$ 2,670 |
| Non-cash                                       | 205           |                                     | 205                             | 2,040                          | 2,245    |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>    |
| Total  | \$ 924        | \$                                  | \$ 924                          | \$ 3,991                       | \$ 4,915 |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>    |

| Six Months Ended<br>Feb. 1, 2003               | Restructuring | Other<br>Charges and<br>Adjustments | Total<br>Charged To<br>Earnings | Adjustments to<br>Goodwill (a) | Total     |
|--|---------------|-------------------------------------|---------------------------------|--------------------------------|-----------|
| In-process research and<br>development (b)     | \$            | \$ 37,600                           | \$ 37,600                       | \$                             | \$ 37,600 |
| Severance (c)                                  | 3,427         |                                     | 3,427                           | 3,439                          | 6,866     |
| Asset write-offs (c)                           | 205           |                                     | 205                             | 2,491                          | 2,696     |
| Lease termination liabilities and<br>other (c) | 67            |                                     | 67                              | 2,380                          | 2,447     |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>     |
| Total  | \$ 3,699      | \$ 37,600                           | \$ 41,299                       | \$ 8,310                       | \$ 49,609 |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>     |
| Cash   | \$ 3,494      | \$                                  | \$ 3,494                        | \$ 5,819                       | \$ 9,313  |
| Non-cash                                       | 205           | 37,600                              | 37,805                          | 2,491                          | 40,296    |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>     |
| Total  | \$ 3,699      | \$ 37,600                           | \$ 41,299                       | \$ 8,310                       | \$ 49,609 |
|  | <hr/>         |                                     | <hr/>                           | <hr/>                          | <hr/>     |

## Edgar Filing: PALL CORP - Form 10-Q

- (a) Reflects restructuring activities related to FSG employees and facilities (refer to Note 3 for discussion of the purchase accounting).
- (b) In the first quarter of fiscal 2003, the Company recorded a charge of \$37,600 to write-off in-process research and development acquired in the acquisition of FSG (refer to Note 3 for further discussion of the purchase accounting).
- (c) At the date of the FSG acquisition, management began formulating integration plans and identifying synergistic opportunities. During the fourth quarter of fiscal 2002 and in the first and second quarters of fiscal 2003, the Company announced and implemented plans to eliminate redundant employees and facilities.

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

Furthermore, during the first quarter of fiscal 2003, the Company reorganized its Life Sciences business such that the Company's hospital and medical OEM sub-segments were combined with the Blood segment to form a new segment called Pall Medical (refer to Note 11 for further discussion). This reorganization, which is expected to reduce manufacturing and selling costs, included employee terminations. Reorganization costs related to the Life Sciences business totaled approximately \$760 and \$2,500 for the three months and six months ended February 1, 2003, respectively.

These actions resulted in the recording of approximately \$6,866 for the six months ended February 1, 2003 in severance related liabilities for an estimated workforce reduction of 230 people, of which approximately 190 employees had been terminated as of February 1, 2003. In addition, liabilities of approximately \$2,447 were recorded for lease termination and other office closure costs, while asset write-offs amounted to approximately \$2,696.

Cash requirements of these actions are expected to be \$9,313 of which \$5,910 has been expended, leaving \$3,403 in accruals reflected on the balance sheet as of February 1, 2003. The expected cash outlays comprise \$6,866 in employee termination benefits and \$2,447 principally related to lease termination liabilities and other office closure costs.

The following table summarizes activity for the six months ended February 1, 2003 related to restructuring liabilities recorded in fiscal 2002 and fiscal 2003:

|                         | Fiscal 2003 |                                       |          | Fiscal 2002 |                                       |           |
|-------------------------|-------------|---------------------------------------|----------|-------------|---------------------------------------|-----------|
|                         | Severance   | Lease Termination Liabilities & Other | Total    | Severance   | Lease Termination Liabilities & Other | Total     |
| Balance at Aug. 3, 2002 | \$          | \$                                    | \$       | \$ 8,937    | \$ 1,487                              | \$ 10,424 |
| Additions               | 6,866       | 2,447                                 | 9,313    |             |                                       |           |
| Utilized                | (4,044)     | (1,866)                               | (5,910)  | (7,060)     | (1,101)                               | (8,161)   |
| Balance at Feb. 1, 2003 | \$ 2,822    | \$ 581                                | \$ 3,403 | \$ 1,877    | \$ 386                                | \$ 2,263  |

**NOTE 5 BALANCE SHEET DETAILS**

The following tables provide details of selected balance sheet items:

|  | Feb. 1, 2003 | Aug. 3, 2002 |
|--|--------------|--------------|
| Accounts receivable, net:              |              |              |
| Accounts receivable                    | \$ 386,468   | \$ 428,759   |
| Less: Allowances for doubtful accounts | 13,453       | 12,906       |
| Total                                  | \$ 373,015   | \$ 415,853   |
| Inventories:                           |              |              |
| Raw materials and components           | \$ 88,060    | \$ 90,807    |
| Work-in-process                        | 44,593       | 40,323       |

Edgar Filing: PALL CORP - Form 10-Q

|   |                             |    |                             |
|---|-----------------------------|----|-----------------------------|
| Finished goods                                  | 147,894                     |    | 125,780                     |
|   | <u>                    </u> |    | <u>                    </u> |
| Total   | \$ 280,547                  | \$ | 256,910                     |
|   | <u>                    </u> |    | <u>                    </u> |
| Property, plant and equipment, net:             |                             |    |                             |
| Property, plant and equipment                   | \$ 1,145,756                | \$ | 1,125,174                   |
| Less: Accumulated depreciation and amortization | 538,029                     |    | 520,079                     |
|   | <u>                    </u> |    | <u>                    </u> |
| Total   | \$ 607,727                  | \$ | 605,095                     |
|   | <u>                    </u> |    | <u>                    </u> |

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

Property, plant and equipment and related accumulated depreciation at February 1, 2003 reflect approximately \$21 million in disposals of fully depreciated assets during fiscal 2003.

**NOTE 6 PRODUCT WARRANTY**

The Company warrants its products against defect in design, materials and workmanship over various time periods. Warranty costs are recorded based upon experience. The warranty accrual as of February 1, 2003 and August 3, 2002 is immaterial to the financial position of the Company and the change in the accrual for the current quarter and the first six months of fiscal 2003 is immaterial to the Company's consolidated results of operations, cash flows or financial position.

**NOTE 7 NOTES PAYABLE AND LONG-TERM DEBT**

On August 6, 2002, the Company completed an offering of \$280,000 of 6% senior notes due on August 1, 2012. The notes are unsecured and unsubordinated obligations of the Company and rank pari passu to its other outstanding unsecured and unsubordinated indebtedness. On October 18, 2002, the Company entered into a \$100,000 LIBOR based variable rate bank loan, which matures in quarterly installments of \$5,000 starting in January 2003 through October 2007. The proceeds of the notes and loan were used to repay the interim credit facility taken to finance the FSG acquisition and for general corporate purposes.

The Company received \$7,533, representing the fair value of receive fixed, pay variable interest rate swaps with an aggregate notional value of \$100,000, which it terminated on November 26, 2002. The terminated swaps relate to the Company's \$100,000 private placement of 7.83% unsecured senior notes due in 2010. As such, these proceeds will be amortized, as a reduction of interest expense, over the remaining life of the underlying notes. Simultaneously, the Company entered into new interest rate swaps involving the \$280,000, 6% notes due on August 1, 2012. The new swaps require the Company to make payments at a variable rate based on LIBOR and receive payments at a fixed rate of 6% on notional amounts totaling \$230,000.

The Company has received a commitment from a financial institution to refinance its Yen 3 billion loan (approximately \$25,000), which is due in its entirety on June 18, 2003, until June 18, 2005. The terms of the commitment will require the Company to make interest payments based on a floating rate based upon Yen LIBOR. As such, the Yen loan is classified as long-term debt in the Company's February 1, 2003 condensed consolidated balance sheet. On March 7, 2003, the Company entered into a forward dated receive variable, pay fixed interest rate swap related to this loan, whereby the Company would receive payments at a variable rate based upon Yen LIBOR and make payments at a fixed rate of .95% on a notional amount of Yen 3 billion. The swap expires on June 18, 2005. As it is the Company's intent to enter into this loan, this swap will be accounted for as a hedge of a forecasted transaction until June 18, 2003. Accordingly, changes in the fair value of the swap will be reflected in other comprehensive income.

**NOTE 8 GOODWILL AND INTANGIBLE ASSETS**

The following table presents goodwill, net of accumulated amortization prior to the adoption of SFAS No. 142, allocated by reportable segment solely for purposes of SFAS No. 142 disclosure:

|                    | Feb. 1, 2003 | Aug. 3, 2002 |
|--------------------|--------------|--------------|
| Medical            | \$ 21,032    | \$ 19,512    |
| BioPharmaceuticals | 27,852       | 31,423       |
| Life Sciences      | 48,884       | 50,935       |
| General Industrial | 148,162      | 180,356      |
| Aerospace          | 6,124        | 6,038        |
| Microelectronics   | 20,799       | 25,644       |
| Industrial         | 175,085      | 212,038      |

Edgar Filing: PALL CORP - Form 10-Q

|       |    |                |    |                |
|-------|----|----------------|----|----------------|
| Total | \$ | <u>223,969</u> | \$ | <u>262,973</u> |
|-------|----|----------------|----|----------------|

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

The change in the carrying amount of goodwill is primarily attributable to the changes in the preliminary allocation of goodwill from the acquisition of FSG discussed in Note 3 and to the changes in foreign exchange rates used to translate the goodwill in the financial statements of foreign subsidiaries at each respective balance sheet date.

Intangible assets, net, consist of the following:

|                                   | Feb. 1, 2003 | Aug. 3, 2002 |
|-----------------------------------|--------------|--------------|
| Patents and unpatented technology | \$ 77,427    | \$ 60,381    |
| Trademarks and other              | 9,274        | 9,605        |
| Subtotal                          | 86,701       | 69,986       |
| Less: Accumulated amortization    | 33,307       | 30,038       |
| Total                             | \$ 53,394    | \$ 39,948    |

Patents and trademarks include costs to register new patents and trademarks. Patents also include expenditures to successfully defend certain patents as well as for paid-up licenses for third-party patents. The increase in patents and unpatented technology is due to the finalization, in the first quarter of fiscal 2003, of the valuation of intangible assets purchased in the FSG acquisition discussed in Note 3.

Amortization expense for these intangible assets for the three months and six months ended February 1, 2003 was \$1,939 and \$3,896, respectively. In fiscal year 2002, amortization expense for the three months and six months ended January 26, 2002 was \$1,317 and \$2,511, respectively. Amortization expense is estimated to be approximately \$3,900 for the remainder of fiscal 2003 and \$7,600 in 2004, \$6,100 in 2005, \$5,600 in 2006, \$5,500 in 2007 and \$4,600 in 2008.

**NOTE 9 COMPREHENSIVE INCOME**

Comprehensive income is comprised of the following:

|   | Three Months Ended |               | Six Months Ended |               |
|---|--------------------|---------------|------------------|---------------|
|   | Feb. 1, 2003       | Jan. 26, 2002 | Feb. 1, 2003     | Jan. 26, 2002 |
| Net income                                | \$ 31,379          | \$ 18,415     | \$ 8,241         | \$ 37,807     |
| Unrealized translation adjustment         | 31,055             | (9,177)       | 34,819           | (7,588)       |
| Income taxes                              | 664                | (927)         | 561              | (669)         |
| Unrealized translation adjustment, net    | 31,719             | (10,104)      | 35,380           | (8,257)       |
| Minimum pension liability adjustment      | (46)               | 39            | (39)             | 25            |
| Income taxes                              | 18                 | (19)          | 15               | 40            |
| Minimum pension liability adjustment, net | (28)               | 20            | (24)             | 65            |



Edgar Filing: PALL CORP - Form 10-Q

|  |           |          |           |           |
|--|-----------|----------|-----------|-----------|
| Change in unrealized<br>accumulated<br>investment gains<br>(losses)      | 630       | (2,528)  | (1,700)   | (5,648)   |
| Income taxes   | 95        | 924      | (44)      | 2,015     |
| Change in unrealized<br>accumulated<br>investment gains<br>(losses), net | 725       | (1,604)  | (1,744)   | (3,633)   |
| Unrealized gains<br>(losses) on<br>derivatives                           | 244       | 417      | 652       | (550)     |
| Income taxes   | (85)      | (146)    | (228)     | 192       |
| Unrealized gains<br>(losses) on<br>derivatives, net                      | 159       | 271      | 424       | (358)     |
| Total comprehensive<br>income  | \$ 63,954 | \$ 6,998 | \$ 42,277 | \$ 25,624 |

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

The net change in unrealized gains (losses) on available-for-sale securities, net of related taxes, consists of the following:

|  | Three Months Ended |               | Six Months Ended |               |
|--|--------------------|---------------|------------------|---------------|
|  | Feb. 1, 2003       | Jan. 26, 2002 | Feb. 1, 2003     | Jan. 26, 2002 |
| Unrealized gains (losses) arising during the period  | \$ 475             | \$ (2,528)    | \$ (1,855)       | \$ (5,648)    |
| Income tax benefit (expense)   | 95                 | 924           | (44)             | 2,015         |
| Net unrealized gains (losses) arising during the period  | 570                | (1,604)       | (1,899)          | (3,633)       |
| Reclassification adjustment for unrealized loss included in net earnings due to impairment in 2003 | 155                |               | 155              |               |
| Change in unrealized accumulated investment gains (losses), net                                    | \$ 725             | \$ (1,604)    | \$ (1,744)       | \$ (3,633)    |

**NOTE 10 STOCK REPURCHASE PROGRAMS**

The Company did not purchase any treasury stock during the first six months of fiscal 2003, and \$140,000 remained to be expended under the Board of Directors' January 2000 authorization of \$200,000, which expired on January 20, 2003.

**NOTE 11 SEGMENT INFORMATION AND GEOGRAPHIES**

During the first quarter of fiscal 2003, the Company reorganized its Life Sciences business to improve profitability. As a result, the hospital and medical OEM sub-segments, which were previously part of the BioPharmaceuticals segment, were combined with the Blood segment to create a new segment called Medical. Life Sciences segment information for prior periods has been restated for these changes. The Company's Form 10-Q for the quarter ended November 2, 2002 presented a table reflecting the fiscal year 2002 quarterly Life Sciences' Medical and BioPharmaceuticals segments restated for the reorganization described above.

[Back to Index](#)

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**  
(In thousands, except per share data)  
(Unaudited)

|   | Three Months Ended |               | Six Months Ended |               |
|---|--------------------|---------------|------------------|---------------|
|   | Feb. 1, 2003       | Jan. 26, 2002 | Feb. 1, 2003     | Jan. 26, 2002 |
| <b>MARKET SEGMENT INFORMATION</b>         |                    |               |                  |               |
| <b>SALES TO UNAFFILIATED CUSTOMERS:</b>   |                    |               |                  |               |
| Medical                                   | \$ 79,119          | \$ 72,733     | \$ 137,085       | \$ 140,168    |
| BioPharmaceuticals                        | 81,652             | 68,345        | 155,715          | 132,874       |
| Total Life Sciences                       | 160,771            | 141,078       | 292,800          | 273,042       |
| General Industrial                        | 140,888            | 80,738        | 267,267          | 160,695       |
| Aerospace                                 | 46,019             | 38,738        | 82,972           | 76,382        |
| Microelectronics                          | 40,844             | 24,881        | 77,693           | 49,435        |
| Total Industrial                          | 227,751            | 144,357       | 427,932          | 286,512       |
| Total                                     | \$ 388,522         | \$ 285,435    | \$ 720,732       | \$ 559,554    |
| <b>OPERATING PROFIT:</b>                  |                    |               |                  |               |
| Medical                                   | \$ 12,665          | \$ 11,597     | \$ 17,192        | \$ 16,196     |
| BioPharmaceuticals                        | 16,039             | 16,350        | 31,211           | 33,268        |
| Life Sciences                             | 28,704             | 27,947        | 48,403           | 49,464        |
| General Industrial                        | 14,213             | 5,832         | 25,037           | 16,296        |
| Aerospace                                 | 12,752             | 7,246         | 21,239           | 18,711        |
| Microelectronics                          | 7,246              | 114           | 12,060           | 144           |
| Industrial                                | 34,211             | 13,192        | 58,336           | 35,151        |
| Subtotal                                  | 62,915             | 41,139        | 106,739          | 84,615        |
| Restructuring and other charges           | (924)              |               | (41,299)         |               |
| General corporate expenses                | (15,730)           | (14,718)      | (31,510)         | (30,066)      |
| Interest expense, net                     | (6,207)            | (2,815)       | (13,473)         | (6,078)       |
| Earnings before income taxes              | \$ 40,054          | \$ 23,606     | \$ 20,457        | \$ 48,471     |
| <b>GEOGRAPHIES: SALES TO UNAFFILIATED</b> |                    |               |                  |               |

Edgar Filing: PALL CORP - Form 10-Q

**CUSTOMERS:**

|                    |    |                   |    |                   |    |                   |    |                   |
|--------------------|----|-------------------|----|-------------------|----|-------------------|----|-------------------|
| Western Hemisphere | \$ | 151,092           | \$ | 126,320           | \$ | 289,159           | \$ | 252,012           |
| Europe             |    | 165,970           |    | 105,284           |    | 301,020           |    | 200,020           |
| Asia               |    | 71,460            |    | 53,831            |    | 130,553           |    | 107,522           |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |
| Total              | \$ | 388,522           | \$ | 285,435           | \$ | 720,732           | \$ | 559,554           |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |

**INTERCOMPANY  
SALES BETWEEN  
GEOGRAPHIC  
AREAS:**

|                    |    |                   |    |                   |    |                   |    |                   |
|--------------------|----|-------------------|----|-------------------|----|-------------------|----|-------------------|
| Western Hemisphere | \$ | 38,627            | \$ | 26,808            | \$ | 78,197            | \$ | 54,863            |
| Europe             |    | 19,578            |    | 14,285            |    | 37,879            |    | 26,365            |
| Asia               |    | 846               |    | 565               |    | 1,720             |    | 966               |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |
| Total              | \$ | 59,051            | \$ | 41,658            | \$ | 117,796           | \$ | 82,194            |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |

**TOTAL SALES:**

|                    |    |                   |    |                   |    |                   |    |                   |
|--------------------|----|-------------------|----|-------------------|----|-------------------|----|-------------------|
| Western Hemisphere | \$ | 189,719           | \$ | 153,128           | \$ | 367,356           | \$ | 306,875           |
| Europe             |    | 185,548           |    | 119,569           |    | 338,899           |    | 226,385           |
| Asia               |    | 72,306            |    | 54,396            |    | 132,273           |    | 108,488           |
| Eliminations       |    | (59,051)          |    | (41,658)          |    | (117,796)         |    | (82,194)          |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |
| Total              | \$ | 388,522           | \$ | 285,435           | \$ | 720,732           | \$ | 559,554           |
|                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |

**OPERATING  
PROFIT:**

|                                    |    |                   |    |                   |    |                   |    |                   |
|------------------------------------|----|-------------------|----|-------------------|----|-------------------|----|-------------------|
| Western Hemisphere                 | \$ | 24,727            | \$ | 13,348            | \$ | 44,676            | \$ | 31,583            |
| Europe                             |    | 29,271            |    | 19,198            |    | 46,998            |    | 34,684            |
| Asia                               |    | 11,192            |    | 8,763             |    | 17,651            |    | 17,567            |
| Eliminations                       |    | (2,275)           |    | (170)             |    | (2,586)           |    | 781               |
|                                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |
| Subtotal                           |    | 62,915            |    | 41,139            |    | 106,739           |    | 84,615            |
| Restructuring and<br>other charges |    | (924)             |    |                   |    | (41,299)          |    |                   |
| General corporate<br>expenses      |    | (15,730)          |    | (14,718)          |    | (31,510)          |    | (30,066)          |
| Interest expense, net              |    | (6,207)           |    | (2,815)           |    | (13,473)          |    | (6,078)           |
|                                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |
| Earnings before<br>income taxes    | \$ | 40,054            | \$ | 23,606            | \$ | 20,457            | \$ | 48,471            |
|                                    |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |    | <u>          </u> |

**[Back to Index](#)**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (In thousands, except per share data).**

You should read the following discussion together with Pall's condensed consolidated financial statements and notes thereto and other financial information included elsewhere in this Form 10-Q report and in our Annual Report on Form 10-K for the fiscal year ended August 3, 2002. As used below, ½% indicates that we have rounded the relevant data up or down to the nearest one-half percentage point. Dollar amounts discussed below are in thousands, except per share dollar amounts. In addition, per share dollar amounts are discussed on a diluted basis.

**Forward-Looking Statements**

The matters discussed in this Form 10-Q may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and in integrating the operations of FSG into the Company's existing business; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets.

**Acquisition and Related Matters**

On April 24, 2002, we acquired the Filtration and Separations Group ( FSG ) from United States Filter Corporation ( US Filter ) for \$360,000 in cash, subject to a post closing adjustment of the purchase price based on the net assets acquired as of April 27, 2002. The adjustment to the purchase price was finalized in the first quarter resulting in additional consideration due to US Filter of \$7,801. The operating results of FSG are reported in our results of operations from April 28, 2002.

The acquisition was accounted for using the purchase method of accounting in accordance with SFAS No. 141, Business Combinations ( SFAS No. 141 ). SFAS No. 141 requires that the total cost of the acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. In the first quarter, we finalized the valuation of in-process research and development and patented and unpatented technology. Accordingly, the preliminary allocation of the purchase price and goodwill were updated for such items, and our net earnings for the six months ended February 1, 2003 reflect the write-off of in-process research and development (refer to Note 4 in the notes accompanying the condensed consolidated financial statements for further discussion).

The methodology for allocating the purchase price to the estimated fair value of in-process research and development, as well as patented and unpatented technology was determined with the assistance of a third party valuation firm. The fair value of in-process research and development was expensed because technological feasibility had not been established and no future alternative uses existed (refer to Note 3 in the notes accompanying the condensed consolidated financial statements). The fair value of the patented and unpatented technology, as well as the in-process research and development, was determined using the income approach, which discounts the expected future cash flows to present value. Failure to achieve expected levels of revenue and net income from these products will negatively impact the return on investment expected at the time the acquisition was completed and may result in impairment charges. We believe that the assumptions used in the valuation of these related items represented a reasonable estimate of the future benefits attributable to them at the time of the acquisition.

The discount rates used in the present value calculations were derived from a weighted average cost of capital analysis and, concerning in-process research and development, adjusted upward to reflect additional risks inherent in the development life cycle. The key assumptions specifically underlying the valuation for purchased in-process research and development consist of an expected completion date for the in-process projects, estimated costs to complete the projects, revenue and expense projections, and discount rates based on the risks associated with the development life cycle of the in-process technology acquired. The development of the in-process research and development technologies remains an uncertainty due to the remaining efforts to achieve technological feasibility, changing customer markets, and significant competitive threats from other companies. The nature of the efforts to develop these technologies into commercially viable products consists principally of planning, designing, experimenting, and testing activities necessary to determine that the technologies can meet market expectations, including functionality and technical requirements. Most of these projects are expected for commercialization within one to two years of the acquisition date. At the date of acquisition, expenditures to complete these projects were not expected to exceed \$6,000.

**Back to Index**

At the date of acquisition, management began formulating integration plans, which contemplate the closure of redundant facilities and the sale of certain businesses. In addition, the synergies created by joining the two organizations have resulted in employee terminations. The condensed consolidated balance sheets at February 1, 2003 and August 3, 2002 reflect liabilities for such items; however, we will continue to finalize and announce other integration plans during fiscal 2003. Finalization of integration plans concerning FSG's facilities and employees in the third quarter will be reported as increases and decreases to goodwill and to the assets acquired and liabilities assumed whereas the financial statement impact of any other integration plans will be reflected in earnings during fiscal year 2003 (refer to Note 4 for discussion of actions taken in the first six months of fiscal 2003).

For more detail regarding the FSG acquisition and regarding restructuring actions taken, please refer to Notes 3 and 4 in the notes accompanying the condensed consolidated financial statements in this report and our Annual Report on Form 10-K for the fiscal year ended August 3, 2002.

**Results of Operations***Review of Consolidated Results*

Sales for the quarter increased 36% to \$388,522 from \$285,435 for the same period last year. For the six months, sales grew 29% to \$720,732. Exchange rates increased reported sales in the quarter and six months by \$24,227, or 8½% and \$31,533, or 6%, respectively, primarily due to the strengthening of the Euro and to a lesser extent the British Pound and Japanese Yen. The weakening of the Argentine Peso partly offset the increases in sales that resulted from the Euro, Pound and Yen. In local currency (i.e., had exchange rates not changed period over period), sales increased 27½% and 23% for the quarter and six months, respectively. Pricing had a positive impact on sales, contributing 1% to our top line growth in the quarter and for the six-month period. For a detailed discussion of sales, refer to *Review of Market Segments and Geographies*.

Compared to last year's pro forma second quarter sales (which include FSG's sales for the three months ended December 31, 2001), sales were up 9½% with all segments contributing to this gain. Growth was particularly strong in Microelectronics, Aerospace (which did not benefit from the FSG acquisition) and BioPharmaceuticals. For the six-month period, sales compared to last year's pro forma sales (which include FSG's sales for the six months ended December 31, 2001), increased 4%. The pro forma sales growth is provided to give an indication of what comparable sales growth would have been had the acquisition occurred at the beginning of each period presented. However, it is not necessarily indicative of what would have occurred if the acquisition had been consummated at those earlier dates due to many factors. These factors include different market approaches and routes to market (i.e., direct sales versus distribution), product rationalization and pricing. In addition, FSG's quarter ended December 31, 2001 was FSG's fourth quarter, which was their strongest sales quarter, and is being incorporated into the comparison of our second quarter growth, which is not our strongest quarter. Like FSG, our strongest quarter is our fourth quarter, which in fiscal 2002, ended on August 3, 2002. A similar situation exists for FSG's sales for the six months ended December 31, 2001 that are incorporated into the six-month pro forma sales comparison.

Cost of sales for the quarter, as a percentage of sales, increased .6% to 51.5% from 50.9% last year. The increase in cost of sales is attributable to the effect of FSG products, which we estimate increased cost of sales by 1.5%. A change in product mix and the benefit of foreign exchange rates partly offset this increase. On a sequential quarter basis, cost of sales, as a percentage of sales, declined 1%, reflecting increased factory throughput and the benefit of foreign exchange. For the six-month period, cost of sales, as a percentage of sales, increased 1.8% to 51.9% from 50.1% last year, primarily due to the effect of FSG products, partly offset by the effect of foreign exchange. Over time, we expect FSG's product margins to improve to levels comparable with Pall's historical margins.

Selling, general and administrative expenses as a percentage of sales for the quarter declined 2.2% to 33.2% from 35.4% last year. For the six-month period, selling, general and administrative expenses as a percentage of sales declined 1.5% to 34.1% from 35.6% last year. The percentage improvement in selling, general and administrative expenses reflects synergies achieved related to our FSG integration efforts, which are estimated at approximately \$5,000 in the quarter and \$8,000 for the six months, and our continued efforts to hold down controllable costs, offset by the impact of increased pension and insurance costs (see next paragraph), foreign exchange (estimated to have increased selling, general and administrative expenses by about \$9,000 in the quarter and \$12,000 in the six month period) and expenses related to the integration of FSG.

We have identified approximately \$30,000 in annualized cost synergies which we expect to realize by the end of fiscal year 2004 as a result of our integration of FSG. We are continuing to evaluate other potential cost savings as well. In fiscal 2003, we now expect an increase in pension costs of approximately \$4,800 due to the downturn in the equities market and decreased interest rates. In addition, we now expect an increase in insurance premiums of

**Back to Index**

approximately \$2,000. We will continue efforts to hold down controllable costs to offset the impact of these increases.

Research and development ( R&D ) expenses in the quarter declined to 3.2% of sales from 4.4% last year, reflecting the elimination of shared research costs with V.I. Technologies ( VITEX ), partly offset by the impact of FSG's R&D this quarter. For the six-month period, R&D declined to 3.5% of sales from 4.5% last year reflecting the factors discussed above. As a result of the modification of our partnership agreement to eliminate shared research costs, the fourth quarter of fiscal 2002 included our final R&D payment to VITEX.

In the second quarter, we recorded restructuring and other charges of \$924 reflecting severance costs of \$652, asset write-offs of \$205 and other exit costs of \$67. Restructuring and other charges for the six-month period were \$41,299, reflecting the write-off of in-process research and development acquired in the FSG acquisition of \$37,600, severance costs of \$3,427, asset write-offs of \$205 and other exit costs of \$67. The charges in the quarter and six-month period were primarily related to the FSG acquisition and the realignment of our Life Sciences business (refer to Note 11 in the notes to the condensed consolidated financial statements for further discussion of the reorganization of our Life Sciences business).

The following table summarizes the activity for the quarter and six months ended February 1, 2003 related to restructuring liabilities recorded in fiscal 2002 and fiscal 2003:

|                         | Fiscal 2003 |                                       |          | Fiscal 2002 |                                       |           |
|-------------------------|-------------|---------------------------------------|----------|-------------|---------------------------------------|-----------|
|                         | Severance   | Lease Termination Liabilities & Other | Total    | Severance   | Lease Termination Liabilities & Other | Total     |
| Balance at Aug. 3, 2002 | \$          | \$                                    | \$       | \$ 8,937    | \$ 1,487                              | \$ 10,424 |
| Additions               | 6,866       | 2,447                                 | 9,313    |             |                                       |           |
| Utilized                | (4,044)     | (1,866)                               | (5,910)  | (7,060)     | (1,101)                               | (8,161)   |
| Balance at Feb. 1, 2003 | \$ 2,822    | \$ 581                                | \$ 3,403 | \$ 1,877    | \$ 386                                | \$ 2,263  |

The details of the charges for the quarter and six-months can be found in Note 4 in the notes accompanying the condensed consolidated financial statements. We expect to recover the costs of the restructuring-related charges within two years from the date of the charge.

Net interest expense increased \$3,392 and \$7,395 for the quarter and six months, respectively, reflecting increased borrowings to fund the FSG acquisition. On November 26, 2002, we received \$8,568 to terminate receive fixed, pay variable interest rate swaps relating to our \$100,000 private placement of 7.83% unsecured senior notes due in 2010. Simultaneously, we entered into new interest rate swaps involving the \$280,000, 6% notes due on August 1, 2012. The new swaps require that we make payments at a variable rate based on LIBOR and receive payments at a fixed rate of 6% on notional amounts totaling \$230,000. As a result of these swaps and reduced debt levels, net interest expense in the second quarter declined \$1,059 as compared to the first quarter.

For the six-month period, the tax rate was 60% due to the non-deductibility of the in-process research and development charge taken in the first quarter. The underlying effective tax rate for the quarter and six months of each year was 22% and 24% for all of fiscal 2002. The improvement in the underlying effective rate as compared to all of fiscal 2002 was a result of fine-tuning our tax planning strategies. We expect to sustain a rate of 22% for the remainder of fiscal 2003.

Net earnings for the quarter were \$31,379, or 25 cents per share, compared with net earnings of \$18,415, or 15 cents per share last year. Excluding the restructuring and other charges of \$585 (after pro-forma tax effect), net earnings and earnings per share on a pro forma basis, for the quarter were \$31,964, or 26 cents per share, respectively. For the six months, net income was \$8,241, or 7 cents per share, compared with net earnings of \$37,807, or 31 cents per share last year. Excluding the restructuring and other charges of \$39,928 (after pro-forma tax effect), net earnings and earnings per share on a pro forma basis, for the six months were \$48,169, or 39 cents per share, respectively. The following table reconciles net earnings and earnings per share as reported, with the pro forma amounts:

Edgar Filing: PALL CORP - Form 10-Q

Back to Index

|   | Three Months Ended<br>Feb. 1, 2003 |                       | Six Months Ended<br>Feb. 1, 2003 |                       |
|---|------------------------------------|-----------------------|----------------------------------|-----------------------|
|   | Net<br>Earnings                    | Earnings<br>per Share | Net<br>Earnings                  | Earnings<br>per Share |
| As reported                                   | \$ 31,379                          | \$ .25                | \$ 8,241                         | \$ .07                |
| Add:<br>Restructuring<br>and other<br>charges | 585                                | .01                   | 39,928                           | .32                   |
| Pro forma                                     | \$ 31,964                          | \$ .26                | \$ 48,169                        | \$ .39                |

Net earnings in the quarter benefited from strong organic sales growth, the controlling of expenses and the benefit of foreign exchange rates, partly offset by the effect of lower margins on sales of FSG products and increased interest costs related to borrowings to fund the FSG acquisition. Concerning the 11 cent increase in earnings per share in the second quarter of this year, we estimate that FSG was accretive to earnings by approximately 3 cents, while organic growth and the benefit of foreign exchange each added another 4 cents. Concerning the 8 cent increase in earnings per share for the six-month period, it is estimated that FSG was accretive to earnings by approximately 3 cents, the benefit of foreign exchange added 4 cents and organic growth contributed 1 cent.

*Review of Market Segments and Geographies*

*Market Segments:*

The tables below present sales by market segment for the quarter and six months with the prior periods restated to reflect the Life Sciences reorganization (as discussed in Note 11 in the notes to the accompanying condensed consolidated financial statements), including the effect of exchange rates and estimated pro forma sales growth including FSG sales for the three and six months ended December 31, 2001 for comparative purposes. The pro forma sales growth is provided to give an indication of what comparable sales growth would have been had the acquisition occurred at the beginning of each period presented. However, it is not necessarily indicative of what would have occurred if the acquisition had been consummated at those earlier dates due to many factors. These factors include different market approaches and routes to market (i.e., direct sales versus distribution), product rationalization and pricing. In addition, FSG's quarter ended December 31, 2001 was FSG's fourth quarter, which was their strongest sales quarter, and is being incorporated into the comparison of our second quarter growth, which is not our strongest quarter. Like FSG, our strongest sales quarter is our fourth quarter, which in fiscal 2002, ended on August 3, 2002. A similar situation exists for FSG's sales for the six months ended December 31, 2001 that are incorporated into the six-month pro forma sales comparison.

| Three Months Ended  | Feb. 1, 2003 | Jan. 26, 2002 | %<br>Change | Exchange<br>Rate<br>Difference | %<br>Change in<br>local<br>currency | Pro forma<br>%<br>Change |
|---------------------|--------------|---------------|-------------|--------------------------------|-------------------------------------|--------------------------|
| Medical             | \$ 79,119    | \$ 72,733     | 9           | \$ 3,368                       | 4                                   | 9                        |
| BioPharmaceuticals  | 81,652       | 68,345        | 19½         | 5,171                          | 12                                  | 11                       |
| Total Life Sciences | 160,771      | 141,078       | 14          | 8,539                          | 8                                   | 10                       |
| General Industrial  | 140,888      | 80,738        | 74½         | 11,138                         | 60½                                 | 3½                       |
| Aerospace           | 46,019       | 38,738        | 19          | 2,307                          | 13                                  | 19                       |
| Microelectronics    | 40,844       | 24,881        | 64          | 2,243                          | 55                                  | 24½                      |
| Total Industrial    | 227,751      | 144,357       | 58          | 15,688                         | 47                                  | 9½                       |
| Total               | \$ 388,522   | \$ 285,435    | 36          | \$ 24,227                      | 27½                                 | 9½                       |





[Back to Index](#)

| Six Months Ended    | Feb. 1, 2003 | Jan. 26, 2002 | %<br>Change | Exchange Rate<br>Difference | %<br>Change in<br>local<br>currency | Pro forma<br>%<br>Change |
|---------------------|--------------|---------------|-------------|-----------------------------|-------------------------------------|--------------------------|
| Medical             | \$ 137,085   | \$ 140,168    | (2)         | \$ 4,510                    | (5½)                                | (2)                      |
| BioPharmaceuticals  | 155,715      | 132,874       | 17          | 7,056                       | 12                                  | 9                        |
| Total Life Sciences | 292,800      | 273,042       | 7           | 11,566                      | 3                                   | 3½                       |
| General Industrial  | 267,267      | 160,695       | 66½         | 14,134                      | 57½                                 | (½)                      |
| Aerospace           | 82,972       | 76,382        | 8½          | 3,046                       | 4½                                  | 8½                       |
| Microelectronics    | 77,693       | 49,435        | 57          | 2,787                       | 51½                                 | 18                       |
| Total Industrial    | 427,932      | 286,512       | 49½         | 19,967                      | 42½                                 | 4                        |
| Total               | \$ 720,732   | \$ 559,554    | 29          | \$ 31,533                   | 23                                  | 4                        |

The discussions of sales growth below are in local currency with the exception of pro forma sales growth or unless indicated otherwise.

Life Sciences sales increased 8% and 3% for the quarter and six months, respectively, as compared with the same periods last year. On a pro forma basis to include FSG, sales grew 10% and 3½% for the quarter and six months, respectively. Life Sciences represented approximately 41% of our total sales for the quarter and six months as compared to 49% for the same periods last year.

Within Life Sciences, Medical segment sales increased 4% as compared to the second quarter of fiscal 2003. Blood sales increased 1½%, while Critical Care increased 11½%. On a sequential quarter basis, Medical sales grew 36½% as reported. For the six-month period, Medical sales declined 5½% reflecting a decline in Blood sales of 11% partly offset by an increase in Critical Care of 10%. The decline in Blood sales was primarily due to a decrease in the level of blood donations as compared to last year. By geography, the Western Hemisphere and Asia reported increases in Medical sales in the quarter, while Europe was down slightly. For the six months, all geographies reported declines in Medical sales compared to the same period last year.

BioPharmaceuticals segment sales grew 12% in both the quarter and for the six-month period, as compared with last year. Sales on a pro-forma basis grew 11% and 9% for the quarter and six months, respectively. Growth in BioPharmaceuticals was attributable to our Pharmaceutical sub-market where sales increased 20% in the quarter and 18% for the six-months. This sub-market has benefited from the Biotechnology industry which is driving growth. All geographies contributed to the gain in Pharmaceuticals.

In BioSciences, the other sub-market in our BioPharmaceuticals segment, sales were down 5½% in the quarter and flat for the six-month period reflecting a switch from a direct sales approach for lab products in Europe, to distribution via VWR International which impacts top line growth but not profitability. Additionally, our lab business has seen a softening in industry demand due to customer consolidations, budget cuts and reduced capital expenditures for robotic systems used in high throughput applications. By geography, the decline in BioSciences for the quarter reflects a shortfall in Europe attributable to the shift in sales approach for lab products. Sales in the Western Hemisphere were flat, while Asia reported moderate growth in this sub-market. For the six-month period, the same trend was evident.

Our Industrial business, where the majority of FSG's sales are reported, accounted for approximately 59% of total sales for the quarter and six-month period, as compared to 51% for the same periods last year. Industrial sales grew 47% and 42½% in the quarter and six-month period, respectively, due to the inclusion of FSG in the periods. Sales on a pro forma basis increased 9½% in the quarter and 4% for the six months reflecting strong growth in Aerospace and Microelectronics.

General Industrial segment sales, which are the largest portion of our Industrial business, grew 60½% in the quarter and 57½% for the six-month period, with all geographies contributing to this gain. All sub-markets within General Industrial achieved double-digit sales growth for the quarter and six months. On a pro forma basis, General Industrial sales grew 3½% in the quarter; however, they were flat for the six-month period. Within General Industrial, sales in our Water Processing sub-market increased 47½% and 72% for the quarter and six months, respectively. The growth in Water Processing reflects our continued successful pilot testing at prospective municipal sites and our market penetration in Eastern Europe and Asia. Sales in our Food & Beverage sub-market grew 142% and 155½% for the quarter and six months, respectively, as the integration of FSG technologies and expertise has significantly broadened our breadth and reach. Sales were particularly strong in Europe, and in Russia.



**Back to Index**

Sales in our Fuels & Chemicals sub-market grew 82½% and 61% for the quarter and six months, respectively. Strategic partnerships are creating excellent growth opportunities and a key growth driver continues to be clean fuels and synthetic fuels initiatives based on environmental driven regulations. Sales in our Power Generation sub-market were also strong, increasing 22½% and 16½% for the quarter and six months, respectively. Power Generation sales growth was particularly strong in Europe and Asia, although we have seen some weakening in the Western Hemisphere and European OEM turbine market.

Aerospace sales grew 13% in the quarter compared to last year, reflecting strong Military and Commercial sales. Military sales grew 18% in the quarter with all geographies contributing to this gain. Growth in Europe was particularly strong. We expect this trend to continue for the balance of the year. Commercial sales grew 7% as we are seeing some strengthening in this market. We still see risk on Commercial Aerospace business as airline bankruptcies or war could negatively impact this portion of the business. By geography, the growth in Commercial Aerospace sales was driven by the Western Hemisphere and to a lesser extent Europe. In the quarter, Military sales comprised approximately 53% of total Aerospace sales as compared to 51% in the second quarter of last year. For the six-month period, Aerospace sales grew 4½% compared to last year reflecting strong Military sales. Commercial Aerospace sales were up slightly for the six-month period. As in the quarter, growth in Military Aerospace was fueled by Europe with the other geographies contributing to this gain as well.

Microelectronics sales grew 55% and 51½% in the quarter and six months, respectively, as compared with last year. On a pro-forma basis, sales increased 24½% and 18% for the quarter and six months, respectively. This is the third consecutive quarter of double-digit sales growth, despite the fact that the semiconductor OEM market remains weak globally and its near term outlook is uncertain. The growth in sales was fueled by the user side of the business. We are also growing in the photolithography market. All geographies reported double-digit sales growth for the quarter and six-month periods.

The consolidated operating profit as a percentage of sales for the quarter increased to 16.2% from 14.4% last year. For the six-month period operating profit was 14.8% as compared to 15.1% for the same period last year.

In Life Sciences, overall operating profit declined to 17.9% from 19.8% reflecting a decline in operating profit margins in the BioPharmaceuticals segment partly offset by an improvement in Medical. For the six-month period, operating profit declined to 16.5% from 18.1% last year reflecting the same trend that was evident in the quarter.

Within Life Sciences, Medical operating profit for the quarter improved sequentially to 16% from 7.8% in the first quarter and was up compared to the 15.9% achieved in the second quarter of last year. Operating profit for the six-months improved to 12.5% from 11.6% last year. The improvements in operating profit reflect manufacturing based cost reduction programs, synergies realized as a result of the reorganization of the critical care and blood businesses (refer to Note 4 for discussion of actions taken in the first six months of fiscal 2003) and the elimination of our R&D cost sharing with VITEX. Additionally, the elimination of most distributor commission payments, which is expected to result in an annual savings of \$3,000, positively impacted operating profit. Operating profit in BioPharmaceuticals decreased to 19.6% in the quarter from 23.9% last year. For the six-month period, operating profit declined to 20% as compared to 25% last year. The decrease in margins was primarily related to a change in product mix. FSG's sales, which carry a lower gross margin, also contributed to the decline. Overall we expect BioPharmaceuticals margins to fluctuate within a range of 20%-25% based on the sales mix.

Overall operating profit in Industrial improved to 15% in the quarter from 9.1% last year. For the six months, operating profit improved to 13.6% from 12.3%. General Industrial operating profit in the quarter improved to 10.1% from 7.2% last year attributable to a change in product mix. For the six months, General Industrial operating profit declined to 9.4% from 10.1% primarily due to the addition of FSG products, which carry lower margins. Aerospace operating profit improved to 27.7% from 18.7% last year primarily due to strong sales in the quarter. For the six-month period operating profit improved to 25.6% from 24.5%. Microelectronics operating profit improved to 17.7% in the quarter and 15.5% for the six-month period from break-even for the same periods last year driven by strong sales growth.

*Geographies:*

By geography, sales in the Western Hemisphere increased 21% in the quarter and 16½% for the six-month period. Exchange rates, primarily related to the weakening of the Argentine Peso, negatively impacted sales by \$1,758 and \$4,295 in the quarter and six months, respectively. Operating profit in the quarter improved to 13% from 8.7% last year. For the six-month period, operating profit increased to 12.2% from 10.3% last year. The increase in operating profit in the Western Hemisphere reflects the improvements in margins achieved in our various business segments as noted above.

**Back to Index**

In Europe, sales increased 36½% and 34½% for the quarter and six months, respectively, compared to last year. The strengthening of European currencies added \$22,272 and \$31,775 in sales, resulting in reported sales growth of 57½% and 50½% in the quarter and six months, respectively. Operating profit in the quarter declined to 15.8% from 16.1% last year reflecting the lower rate of profit on FSG products. Operating profit for the six-month period declined to 13.9% from 15.3%.

Sales in Asia increased 26% and 17½% in the quarter and six months, respectively. The strengthening of Asian currencies added \$3,713 and \$4,053 in sales, resulting in reported sales growth of 33% and 21½% in the quarter and six months, respectively. Operating profit declined to 15.5% from 16.1% last year primarily due to lower FSG margins and a change in product mix. For the six-month period, operating profit declined to 13.3% from 16.2% reflecting the same factors cited above.

General corporate expenses were up slightly in the quarter and six-month period reflecting increased pension and insurance costs.

**Liquidity and Capital Resources**

The Company's balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars. In comparing spot exchange rates at February 1, 2003 to those at the end of fiscal 2002, the European currencies (especially the Euro and the British Pound) have strengthened against the U.S. dollar, while the Argentine Peso has weakened. The Yen was flat as compared to the spot rate used at the end of fiscal 2002.

The acquisition of FSG in the third quarter of fiscal 2002 was initially funded via a \$360,000 364-day variable rate credit facility. On August 6, 2002, we issued \$280,000 of 10-year bonds at an annual interest rate of 6%. The proceeds were utilized to repay a portion of the interim acquisition credit facility. Additionally, on October 18, 2002, we refinanced the remainder of the acquisition credit facility with a \$100,000 term loan bearing interest based on LIBOR. We received \$7,533, representing the fair value of receive fixed, pay variable interest rate swaps with an aggregate notional value of \$100,000, which we terminated on November 26, 2002. The terminated swaps relate to our \$100,000 private placement of 7.83% unsecured senior notes due in 2010. As such, these proceeds will be amortized, as a reduction of interest expense, over the remaining life of the underlying notes. Simultaneously, we entered into new interest rate swaps involving the \$280,000, 6% notes due on August 1, 2012. The new swaps require that we make payments at a variable rate based on LIBOR and receive payments at a fixed rate of 6% on notional amounts totaling \$230,000.

We have received a commitment from a financial institution to refinance our Yen 3 billion loan (approximately \$25,000), which is due on June 18, 2003, until June 18, 2005. The terms of the commitment will require us to make interest payments based on a floating rate based upon Yen LIBOR. As such, the Yen loan is classified as long-term debt in our February 1, 2003 condensed consolidated balance sheet. On March 7, 2003, we entered into a forward dated receive variable, pay fixed interest rate swap related to this loan, whereby we would receive payments at a variable rate based upon Yen LIBOR and make payments at a fixed rate of .95% on a notional amount of Yen 3 billion. The swap expires on June 18, 2005. As it is our intent to enter into this loan, this swap will be accounted for as a hedge of a forecasted transaction until June 18, 2003. Accordingly, changes in the fair value of the swap will be reflected in other comprehensive income.

Net cash provided by operating activities for the first six months of fiscal 2003 was \$75,097, an increase of \$11,495 compared to the same period of fiscal 2002. The increase in cash flow from operations was generated by increased earnings as well as by accounts receivable, partly offset by increased inventory levels and lower levels of accounts payable. Additionally, the first quarter of fiscal 2002 included a rebate payment to a major blood customer. The increase in inventory reflects the effects of foreign exchange (see next paragraph) and increased work-in-process and replenishment of stock for anticipated third quarter shipments.

Working capital was approximately \$515,000, a ratio of 2.4, at February 1, 2003 as compared to \$478,000, a ratio of 2.1 at August 3, 2002. Accounts receivable days sales outstanding was 87 days, as compared to 94 at August 3, 2002, while inventory turns have improved to 2.9 from 2.8. The effect of foreign exchange increased inventory, accounts receivable and other current assets by \$15,906, \$9,540 and \$1,711, respectively, as compared to the end of fiscal 2002. Additionally, foreign exchange increased accounts payable and other current liabilities by \$9,977 and income taxes payable by \$1,049.

When operating the business day-to-day, excluding acquisitions but including funding capital expenditures and buying back common stock, our guideline is to keep net debt (debt net of cash, cash equivalents and short-term investments) at 25% to 30% of total capitalization (net debt plus equity). Net debt decreased by \$40,905 compared with year-end fiscal 2002. The impact of foreign exchange rates accounted for \$4,798 of the reduction, while \$5,038 of the reduction was related to a change in the fair value of our interest rate swaps which are carried as part of debt.

**Back to Index**

Overall, net debt, as a percentage of total capitalization, was 38.9% as compared to 41.3% at year-end fiscal 2002. Our goal for fiscal 2003 is to reduce net debt by \$50,000 to facilitate our return to the debt levels that existed prior to the acquisition as quickly as possible. Therefore, we did not purchase treasury stock during the first six months of fiscal 2003, and \$140,000 remained to be expended under the Board of Directors January 2000 authorization of \$200,000, which expired in January of 2003. We consider our existing lines of credit, along with the cash generated from operations, to be sufficient for future growth. It is management's intention to refinance any unpaid amounts under the unsecured senior revolving credit facility when it expires in 2005.

Capital expenditures were \$28,235 of which \$13,779 was spent in the second quarter. Depreciation expense was \$18,892 and \$37,973 in the quarter and six months, respectively. Amortization expense was \$2,001 and \$4,003 for the quarter and six months, respectively. Our goal is to keep capital expenditures at or below \$70,000 in fiscal 2003.

As mentioned previously, we modified our partnership agreement with VITEX to eliminate shared research costs. We expect to fund a final \$4,000 milestone payment for equity, during the third quarter, contingent on VITEX securing an additional \$11,000 in equity financing, on or before September 30, 2003. As of February 1, 2003, VITEX has borrowed \$2,500 against the one-year \$5,000 line of credit extended to it by the Company and later in the month of February borrowed the remaining \$2,500 available under the line of credit.

On March 4, 2003, we acquired the assets, primarily manufacturing equipment and intellectual property, of Whatman HemaSure Inc., a wholly owned subsidiary of Whatman plc (the seller) for a purchase price of \$5,950. In addition, the agreement contains a non-compete agreement for a period of 7½ years, which precludes the seller from engaging in the blood filter business during that time.

**ITEM 4. CONTROLS AND PROCEDURES**

Within 90 days prior to the filing date of this Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective.

There have been no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's internal controls subsequent to the date the Company carried out its evaluation.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS.**

In February 1988, an action was filed in the Circuit Court for Washtenaw County, Michigan (Court) by the State of Michigan (State) against Gelman Sciences Inc. (Gelman), a subsidiary acquired by the Company in February 1997. The action sought to compel Gelman to investigate and remediate contamination near Gelman's Ann Arbor facility and requested reimbursement of costs the State had expended in investigating the contamination, which the State alleged was caused by Gelman's disposal of waste water from its manufacturing process. Pursuant to a consent judgment entered into by Gelman and the State in October 1992 (amended September 1996 and October 1999), which resolved that litigation, Gelman is remediating the contamination without admitting wrongdoing. In February 2000, the State Assistant Attorney General filed a Motion to Enforce Consent Judgment in the Court seeking approximately \$4,900,000 in stipulated penalties for the alleged violations of the consent judgment and additional injunctive relief. Gelman disputed these assertions. In July 2000, the Court took the matter of penalties under advisement. The Court issued a Remediation Enforcement Order requiring Gelman to submit and implement a detailed plan that will reduce the contamination to acceptable levels within five years. The Company's plan has been submitted to, and approved by, both the Court and the State. In the opinion of management, to date the Court has expressed its satisfaction with the Company's progress. Subsequently, the State asserted in correspondence dated June 5, 2001 that additional stipulated penalties in the amount of \$141,500 were owed for a separate alleged violation of the consent judgment. The Court found that a substantial basis for Gelman's position existed and again took the State's request under advisement, pending the results of certain groundwater monitoring data. On August 9, 2001, the State made a written demand for reimbursement of \$227,462 plus interest it has allegedly incurred for groundwater monitoring. Gelman considers this claim barred by the consent judgment. The Company's balance sheet at February 1, 2003 contains reserves of approximately \$16,400,000, which relates mainly to the aforementioned cleanup. In the opinion of management, the Company is in substantial compliance with applicable environmental laws and its current accruals for environmental remediation are adequate.

**Back to Index**

**ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.**

- (a) The Annual Meeting of Shareholders of the Company was held on November 20, 2002.
- (b) Not required. Proxies for the meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934. There was no solicitation in opposition to management's director nominees as listed in the proxy statement and all of management's nominees were elected.
- (c) The matters voted upon and the results of the voting were as follows:

Holders of 107,527,088 shares of common stock voted either in person or by proxy for the election of four directors. The number of votes cast for each nominee were as indicated below:

| Director             | Total vote for each director | Total vote withheld each director |
|----------------------|------------------------------|-----------------------------------|
| Abraham Appel        | 103,227,123                  | 4,299,965                         |
| Ulric Haynes, Jr.    | 105,457,995                  | 2,069,093                         |
| Jeremy Hayward-Surry | 105,053,144                  | 2,473,944                         |
| Edwin W. Martin, Jr. | 105,458,018                  | 2,069,070                         |

- (d) Not applicable.

**ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.**

- (a) Exhibits

See the index to exhibits for a list of exhibits filed herewith.

- (b) Reports on Form 8-K.

The Company filed no reports on Form 8-K during the three months ended February 1, 2003.

[Back to Index](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

March 18, 2003

PALL CORPORATION

/s/ JOHN ADAMOVICH, JR  
John Adamovich, Jr  
Chief Financial Officer  
and Treasurer

March 18, 2003

/s/ LISA KOBARG  
Lisa Kobarg  
Chief Accountant



[Back to Index](#)

**CHIEF EXECUTIVE OFFICER CERTIFICATION**

I, Eric Krasnoff, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pall Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of Pall Corporation as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
  - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and
  - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

March 18, 2003

/s/ ERIC KRASNOFF  
Eric Krasnoff  
Chief Executive Officer

[Back to Index](#)

**CHIEF FINANCIAL OFFICER CERTIFICATION**

I, John Adamovich, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pall Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of Pall Corporation as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
  - a. designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b. evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and
  - c. presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
  - a. all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

March 18, 2003

/s/ JOHN ADAMOVICH, JR.  
John Adamovich, Jr.  
Chief Financial Officer

[Back to Index](#)

**Exhibit Index**

**Exhibit**

**Number Description of Exhibit**

- 2(i)\* Stock Purchase Agreement dated February 14, 2002, by and between the Registrant and United States Filter Corporation, filed as Exhibit 2 to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended January 26, 2002.
- 2(ii)\* Amendment dated April 24, 2002, to Stock Purchase Agreement dated February 14, 2002, by and between the Registrant and United States Filter Corporation, filed as Exhibit 2.2 to the Registrant's Current Report on Form 8-K bearing cover date of April 24, 2002.
- 3(i)\* Restated Certificate of Incorporation of the Registrant as amended through November 23, 1993, filed as Exhibit 3(i) to the Registrant's Annual Report on Form 10-K for the fiscal year ended July 30, 1994.
- 3(ii)\* By-Laws of the Registrant as amended on October 3, 2002, filed as exhibits 3(ii) and 3(iii) to the Registrant's Annual Report on Form 10-K for the fiscal year ended August 3, 2002.
- 4(i)\* Credit Agreement dated as of August 30, 2000 by and among the Registrant and Fleet Bank, National Association as Administrative Agent, The Chase Manhattan Bank as Syndication Agent, Wachovia Bank, N.A. as Documentation Agent and The Lenders Party Thereto, filed as Exhibit 4 to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended October 28, 2000.
- 4(ii)\* Indenture dated as of August 1, 2002, by and among Pall Corporation as Issuer, the Guarantors named therein, as Guarantors, and The Bank of New York, as Trustee, filed as Exhibit 4(iii) to the Registrant's Annual Report on Form 10-K for the fiscal year ended August 3, 2002.

The exhibits filed herewith do not include other instruments with respect to long-term debt of the Registrant and its subsidiaries, inasmuch as the total amount of debt authorized under any such instrument does not exceed 10% of the total assets of the Registrant and its subsidiaries on a consolidated basis. The Registrant agrees, pursuant to Item 601(b) (4) (iii) of Regulation S-K, that it will furnish a copy of any such instrument to the Securities and Exchange Commission upon request.

- 99.1 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
- 99.2 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

\* Incorporated herein by reference.

Exhibits filed herewith